Dr. Voodoo,
Long time no hear. Speaking of hearing, have you heard of these apparent competitors to AGNT?
>>BUDAPEST, Hungary, Dec. 13 /PRNewswire/ -- ComGenex Inc. of Budapest, Hungary, announced today that it redesigned and upgraded its MiniReactor(TM) combinatorial and high throughput synthesis instruments. The upgraded instruments have now been made commercially available.
Originally developed by ComGenex as a part of their ComGenex Matrix Technology(TM)(CMT) high throughput synthesis approach, the MiniReactors(TM) were launched commercially in 1998. From the original design improvements have been made to increase the performance and applicability of the instrument and GlaxoSmithKline are the first recipients of the upgraded devices.
The MiniReactor(TM) is a ul-ml scale combinatorial chemistry synthesis reaction device used to create large numbers of discrete compounds for the discovery of new chemical entities. Operating either as a stand alone reaction station or incorporated into larger synthesis platforms, the MiniReactor(TM) is a key tool for ComGenex in it's synthesis of discrete compounds and as a research tool for many leading research groups worldwide.
Laszlo Urge Ph.D., CEO of ComGenex commented ``We were pleased that GlaxoSmithKline recognized the relevance of our synthesis technology and the impressive specifications of these newly redesigned instruments. This is another example of how our clients and partners can benefit from our integrated technology and solutions in a wide range of service portfolio.''
David Emiabata-Smith Ph.D. team leader of laboratory automation at GlaxoSmithKline commented ``We have had much success with this reactor in the past and given the increasing interest in its application within GlaxoSmithKline we were keen to incorporate these new devices and extend our synthetic capabilities.''
About ComGenex Inc.
ComGenex is an integrated drug discovery chemistry provider for the pharmaceutical and biotechnology industries. The company is the first and presently the largest independent discovery chemistry supplier in Europe, and a leader in discovery related ADME and stability services. ComGenex maintains various in-house proprietary combinatorial technologies in the areas of chemistry, instrumentation, high throughput analytics, informatics and supports the industry's first e-Commerce system in the drug discovery field, ComGenexDirect(TM).
ComGenex focuses on developing a complete discovery chemistry solution for its more than 200 customers and partners world-wide, through compound library design, synthesis of non-exclusive and exclusive libraries. Since its inception in 1992, ComGenex has developed a significant expertise and knowledge base not only in biochemical sciences but also in providing a range of suitable services to its life sciences clients and partners, from compound library provision, lead optimisation and ``hit-to-lead'' services to contracted FTE and long term collaboration. For more information on ComGenex, visit www.comgenex.com <<
snip
OT: Was my "Fun with Ticker Symbols" thread too esoteric to succeed?
Cheers, Tuck |
